Roche gains CD25 program via Tusk takeout

Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to

Read the full 247 word article

User Sign In